India, May 18 -- Lakewood-Amedex Biotherapeutics, Inc. (LABT) shares declined 20.00 percent to $1.2000, down $0.3000 on Monday, even after the clinical-stage biotechnology company reported positive manufacturing and stability data for its lead antimicrobial candidate, Nu-3.
The stock is currently trading at $1.2000, compared with a previous close of $1.5000 on the Nasdaq. It opened at $1.3600 and traded between $1.0700 and $1.4700 during the session, with volume reaching 34.73 million shares, well above the average daily volume of 3.31 million shares.
The company said Nu-3, a topical treatment being developed for mildly infected diabetic foot ulcers, demonstrated favorable manufacturing progress and long-term stability. Drug substance rem...